With 32% ownership, Nautilus Biotechnology, Inc. (NASDAQ:NAUT) insiders have a lot riding on the company's future [Yahoo! Finance]
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "sell" rating. They now have a $1.75 price target on the stock.
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award
Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference
Nautilus Biotechnology Reports Third Quarter 2024 Financial Results